The following post comes from Austin Shaffer, a 2L at Scalia Law and a Research Assistant at CPIP. By Austin Shaffer This past fall, the Department of Justice (DOJ) and […]
[Archived Post] USPTO-DOJ Workshop on Promoting Innovation in the Life Science Sector: Day One Recap
The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at CPIP. By Colin Kreutzer This past fall, the United States Patent and Trademark […]
[Archived Post] IP Scholars Question the Legality and Wisdom of Joint AG Proposal to Seize Remdesivir Patents
The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at CPIP. By Colin Kreutzer While the vaccines are starting to roll out in […]
[Archived Post] Professor Joanna Shepherd Explains Pharmaceutical Product Hopping in New CPIP Policy Brief
CPIP has published a new policy brief by Joanna M. Shepherd, Vice Dean and Thomas Simmons Professor of Law at Emory University School of Law. The brief, entitled The Legal […]
[Archived Post] Recent Developments in the Life Sciences: The Continuing Assault on Innovation by Antitrust Plaintiffs in Lantus
By Erika Lietzan In February, the U.S. Court of Appeals for the First Circuit held, in a direct purchaser antitrust action, that an innovative pharmaceutical company marketing an injectable drug […]
[Archived Post] IP Industries Step Up in This Time of Crisis
The global COVID-19 pandemic has challenged multiple aspects of modern society in a short time. Health and public safety, education, commerce, research, arts, and even basic government functions have had […]
[Archived Post] The Tradeoffs Involved in New Drug Approval, Expanded Access, and Right to Try
The following post comes from CPIP Senior Fellow for Life Sciences Erika Lietzan, and it is cross-posted here from the Objective Intent blog with permission. This note explains some of […]
[Archived Post] “No Combination Drug Patents Act” Stalls, but Threats to Innovation Remain
By Kevin Madigan & Sean O’Connor This week, the Senate Judiciary Committee was to mark up a bill limiting patent eligibility for combination drug patents—new forms, uses, and administrations of […]
[Archived Post] Recognizing the Limits of Government Procurement in the Pharmaceutical Industries
While recent headlines claim that rising drug prices can be easily addressed through government intervention, the procedures involved with government use of patented technologies are complex and often misunderstood. In […]
[Archived Post] A Cure Worse Than the Disease? Proposed Changes to European Patent Law are Threatening Pharmaceutical Innovation
Innovation is all around us. We love and appreciate the latest video games, software apps, and smartphones. We await the integration of self-driving cars and other forms of artificial intelligence. […]